| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6d8fc75c511126eee855ff35d9db61f6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 |
| filingDate |
2014-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d33b2f3be89558150b3ed3cde9614988
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c889b053b08e4647d46909c05277c0fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0137a7ad786a89abb0d5d17f90f60fa7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f07611719eb5e06b86be904a66541ff1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc7d59e9c421e8076d6e9fa965459b22 |
| publicationDate |
2015-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015061724-A1 |
| titleOfInvention |
Selective androgen receptor modulator and chemotherapeutic agent for treating muscle wasting in cancer patients |
| abstract |
This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; 5 increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023287986-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110433172-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110433172-B |
| priorityDate |
2013-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |